Skip to main content
ENDO 2026 Main banner

Topic: Receptor Biology and Signal Transduction
Session Type: Symposium

SY53 - Degrader Revolution: Reimagining Hormone Receptor Targeting

Monday, June 15, 2026
4:30 PM - 6:00 PM CT
Location: Room W179

    Symposium Chair(s)

  • Donald McDonnell, PhD

    Professor
    Duke University School of Medicine
    Durham, NC, United States

    Disclosure(s): Adara Pharmaceuticals: Owner/Co-Owner Founder/Co-Founder (); Bristol Myers Squibb: Consultant (), Grant Recipient (); Coregen: Advisory Board (); Daichi Sankyo: Consultant (); Foghorn Therapeutics: Consultant (); Interdict Bio: Advisory Board (); Menarini: Grant Recipient (), Intellectual property (); Pappas Capital: Advisory Board (); Parabilis Medicine: Consultant (); Precede Therapeutics: Consultant (), Grant Recipient (); Rappta Pharmaceuticals: Advisory Board (); Stemline: Consultant ()

  • Daniel Frigo, PhD

    Professor
    University of Texas MD Anderson Cancer Center
    Houston, TX, United States

    Disclosure(s): Barricade Therapeutics: Familial relationship (); Biocity Biopharmaceuticals: Familial relationship (); March Biosciences: Familial relationship ()

Disclosure(s):
Donald McDonnell, PhD: Adara Pharmaceuticals: Owner/Co-Owner Founder/Co-Founder (); Bristol Myers Squibb: Consultant (), Grant Recipient (); Coregen: Advisory Board (); Daichi Sankyo: Consultant (); Foghorn Therapeutics: Consultant (); Interdict Bio: Advisory Board (); Menarini: Grant Recipient (), Intellectual property (); Pappas Capital: Advisory Board (); Parabilis Medicine: Consultant (); Precede Therapeutics: Consultant (), Grant Recipient (); Rappta Pharmaceuticals: Advisory Board (); Stemline: Consultant ()
Daniel Frigo, PhD: Barricade Therapeutics: Familial relationship (); Biocity Biopharmaceuticals: Familial relationship (); March Biosciences: Familial relationship ()

Proteolysis targeting chimeras (PROTACs) have emerged as a novel biochemical modality that promotes ubiquitination and proteasomal degradation of specific intracellular protein targets. Recent pre-clinical and clinical trials have revealed a potential for therapeutic efficacy of PROTACs targeting various hormone receptors. This session will describe the mechanisms of PROTACs and present the evidence and limitations of their use to deplete androgen receptor in polycystic ovary syndrome and estrogen receptor in advanced breast cancer.

Presentations:

  • 4:30 PM - 5:00 PM CT
    PR PROTACs in Breast Cancer

    Symposium Speaker: Shaomeng Wang, PhD – University of Michigan Medical School

  • 5:00 PM - 5:30 PM CT
    Nuclear Receptor Degradation Mechanisms: PXR as a Case Study

    Symposium Speaker: Taosheng Chen, PhD (he/him/his) – St. Jude Children's Research Hospital

  • 5:30 PM - 6:00 PM CT
    Androgen Receptor Degradation: Redefining Therapeutic Targeting in PCOS

    Symposium Speaker: Damian Romero, Ph.D. – Univ. of Mississippi Medical Center